OBM Genetics is an international Open Access journal published quarterly online by LIDSEN Publishing Inc. It accepts papers addressing basic and medical aspects of genetics and epigenetics and also ethical, legal and social issues. Coverage includes clinical, developmental, diagnostic, evolutionary, genomic, mitochondrial, molecular, oncological, population and reproductive aspects. It publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Publication Speed (median values for papers published in 2023): Submission to First Decision: 5.1 weeks; Submission to Acceptance: 17.0 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)

Current Issue: 2024  Archive: 2023 2022 2021 2020 2019 2018 2017

Special Issue

Pharmacogenetics and Chronic Pain

Submission Deadline: November 30, 2020 (Open) Submit Now

Guest Editor

Ana M Peiró, MD, PhD

Neuropharmacology on Pain and Functional Diversity (NED), Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain;
Clinical Pharmacology Unit, Department of Health of Alicante-General Hospital, Alicante, Spain;
Professor, Clinical Pharmacology Department. Universidad Miguel Hernandez, Alicante, Spain.

Website | E-Mail

Research Interests: Pharmacogenetics; chronic pain; genes; pain treatment; genetic biomarker; genetic variability; pain management

About This Topic

Genome-wide association studies and candidate gene findings suggest that genetic approaches may help choose the most appropriate drug and dosage while preventing adverse drug reactions. This is the field that addresses Precision Medicine in opioid use evaluating variations in the DNA sequence that could be responsible for different individual analgesic response. We review potential gene biomarkers with best overall convergent functional evidence for opioid use in pain management. Polymorphisms can modify pharmacodynamics (i.e. mu opioid receptor, OPRM1) and pharmacokinetics (i.e. CYP2D6 phenotypes) pathways altering opioid effectiveness, consumption, side effects or even more, prescription opioid use dependence vulnerability. This review provides a summary these candidate variants for the translation of genotype into clinically useful information in pain medicine.

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (genetics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!